SCM
AVIR icon

Sterling Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Sterling Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64K Sell
1,429
-889
-38% -$4.42K ﹤0.01% 2460
2026
Q1 		$12.5K Sell
2,318
-1,779
-43% -$8.17K ﹤0.01% 2260
2025
Q4 		$14.6K Sell
4,097
-1,192
-23% -$3.79K ﹤0.01% 2403
2025
Q3 		$15.3K Buy
5,289
+3,109
+143% +$10.6K ﹤0.01% 2264
2025
Q2 		$7.85K Buy
2,180
+849
+64% +$2.53K ﹤0.01% 2277
2025
Q1 		$3.98K Sell
1,331
-1,141
-46% -$3.56K ﹤0.01% 2278
2024
Q4 		$8.28K Buy
2,472
+2,227
+909% +$7.4K ﹤0.01% 2248
2024
Q3 		$821 Buy
+245
New +$888 ﹤0.01% 2641

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sterling Capital Management's AVIR Position: Q2 2026 in Review

Sterling Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 38% in Q2 2026, selling an estimated $4.42K and leaving 1,429 shares worth $6.64K. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

Sterling Capital Management first reported a position in AVIR in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.3K in Q3 2025. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Sterling Capital Management held 1,429 shares of Atea Pharmaceuticals worth $6.64K as of Q2 2026.
  • Sterling Capital Management sold 889 Atea Pharmaceuticals shares in Q2 2026, an estimated $4.42K.
  • Atea Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2460 holding.
  • Sterling Capital Management first reported a position in Atea Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Atea Pharmaceuticals position peaked at $15.3K in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.